NASDAQ:APTO
Aptose Biosciences Stock News
$1.26
-0.0100 (-0.787%)
At Close: Apr 17, 2024
What Makes Aptose Biosciences (APTO) a New Buy Stock
01:01pm, Friday, 05'th Apr 2024
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript
08:38pm, Tuesday, 26'th Mar 2024
Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
04:30pm, Monday, 18'th Mar 2024
SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted
Why Is Aptose Biosciences (APTO) Stock Down Today?
08:36am, Friday, 26'th Jan 2024
Aptose Biosciences (NASDAQ: APTO ) stock is on the move Friday after announcing details for a public offering of the clinical-stage biotechnology company's shares. Aptose Biosciences is selling 4,912
Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript
07:22pm, Thursday, 09'th Nov 2023
Aptose Biosciences Inc. (NASDAQ:APTO ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relat
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
09:15am, Monday, 30'th Oct 2023
Tusp etinib (TUS) Combination with Venetoclax (VEN) Clinical Findings Highlighted TUS Targets VEN Resistance Mechanisms to Re-sensitize VEN Failure Patients to VEN 44% ORR with TUS/VEN in Difficul
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
07:11am, Thursday, 26'th Oct 2023
SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted ag
Aptose to Present at the Cantor Global Healthcare Conference
07:45am, Monday, 18'th Sep 2023
SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
07:30am, Thursday, 24'th Aug 2023
SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Aptose Biosciences Inc. (APTO) Q2 2023 Earnings Call Transcript
11:01pm, Thursday, 10'th Aug 2023
Aptose Biosciences Inc. (NASDAQ:APTO ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Corporate Communications and Investor Relations William Rice
3 Stocks With 1,000% Upside Potential
10:03am, Sunday, 21'st May 2023
If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potentia
Aptose Biosciences Inc. (APTO) Q1 2023 Earnings Call Transcript
09:22pm, Monday, 08'th May 2023
Aptose Biosciences Inc. (NASDAQ:APTO ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Susan Pietropaolo – Corporate Communications & Investor Relations William G. Rice
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
07:01am, Thursday, 04'th May 2023
SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted ag
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
07:01am, Monday, 24'th Apr 2023
SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted
Aptose to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
04:01pm, Monday, 10'th Apr 2023
SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing
